ORIC | Ticker Profile - Titan Protect

ORIC

ORIC Pharmaceuticals, Inc.

Healthcare · Biotechnology · NMS

$7.50

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$888M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.53

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-42.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$21.00

+180% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

https://www.oricpharma.com

Country: United States Employees: 104 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.433

Positive but modest risk-adjusted returns

Kelly Fraction

0.0225

Modest edge detected — smaller position warranted

Calmar Ratio

0.000

Drawdown risk outweighs the returns — higher risk profile

Annual Return

0.0%

Historical annualised return based on price data

Max Drawdown

-66.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.11

Moves slightly more than the broader market

52W High

$14.93

50% below the year high

52W Low

$6.89

9% above the year low

Avg Volume

1,801,203

Average daily shares traded — higher means easier to buy and sell

Short Ratio

15.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

21.4%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.39

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.62

Meaningful debt load — monitor closely

Current Ratio

16.33

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

15.87

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-67,968,624

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-135,214,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$21.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go